Biogen Inc.
Biogen Inc. is a biopharmaceutical company focused on neuroscience, with its dominant political signal being $9.16M in annual payments to doctors and recent congressional purchases of its stock.
BusinessWhat BIIB does
Biogen Inc. is a biotechnology company that discovers, develops, and delivers therapies for neurological and neurodegenerative diseases. Its revenue is derived from products for conditions such as multiple sclerosis, spinal muscular atrophy, and Alzheimer's disease. The company operates in a highly regulated environment dependent on drug pricing, reimbursement, and FDA approval pathways.
12 months past · 3 months futureBIIB activity timeline
Executive Branch ConflictsBIIB held by Trump-administration officials
Lifetime Government AwardsBIIB federal contracts
BIIB doesn't hold direct federal contracts.
Verified via USASpending.gov: $0 reported in direct prime-contract awards. Companies in this position typically sell federal services indirectly through prime contractors and integrators (e.g., Lockheed Martin, Booz Allen, Microsoft Azure) or through commercial channels that don't appear in USASpending data.
Smart Money · 13F HoldingsHedge funds holding BIIB
Politicians Trading BIIBMembers of Congress with recent BIIB positions
Congressional TradesWho in Congress is trading BIIB
Corporate Insiders · Form 4What CEOs, CFOs, and directors are doing with their own stock
No Form 4 activity recorded in the last 180 days.
Bills Affecting BIIBLive legislation impacting this stock
Political ProfileWhere BIIB sits in Washington
[object Object]
STRUCTURAL: High regulatory density (score 85) from 8 identified pharma bills. EVIDENTIARY: Three distinct congressional purchasers (C001123, K000389, B001327) across 7 transactions in the last 12 months, but offset by zero corporate insider buys (`get_corporate_insider_signal.total_buys: 0`), zero lobbying spend, and zero federal contracts. Net: Evidentiary congressional interest is countered by a lack of structural political investment and insider conviction.
Regulatory ExposureThreats & opportunities
Regulatory threats
-
Drug pricing and reimbursement legislationCongress, HHS/CMS"Recent bill_impacts list 8 pharma-sector bills with estimated revenue impacts ranging from $15M to $22.5M."
Regulatory opportunities
- No specific regulatory opportunities flagged.
Capitol Hill AlliesChampions & critics
Live signals + predictions for BIIB — for Founders
The free page above gives you the public record. Members see the real-time intelligence layer on top of it:
- Live 7-layer signal scores when Congress trades BIIB
- Bill Pass Index v2 odds for every bill on the watch list
- Iron Triangle alerts (committee × donor × trade)
- SEC Form 4 cluster detection (CEO + CFO + director buys)
- Whale-Opportunity expected-value ranking
- Custom watchlist alerts via email + Discord